Zydus Lifesciences Ltd
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Filing Details / Description
Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across ....